FIRST TRACKS BIOTHERAPEUTICS
TRAXNASDAQTrading Snapshot
- Day Range
- $35.50 – $36.68
- 52-Week Range
- $14.72 – $49.91
- Volume
- $3.54B
- Avg Volume
- $4.27B
- Shares Outstanding
- 34.9M
- Next Earnings
- Nov 22, 2026
Fundamentals Snapshot
- Annual Revenue
- $99M
- Last Q Revenue
- $25M
- P/E Ratio
- -9.2
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-3.70
- Dividend Yield
- 0.00%
Why Investors Own TRAX
- ✓High-growth profile — revenue up +44.1% YoY with expanding US Equity exposure.
- ✓Healthy economics — 69% gross margin and 16% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
FIRST TRACKS BIOTHERAPEUTICS
TRAX
StockOtter · stockotter.spaceAbout FIRST TRACKS BIOTHERAPEUTICS
First Tracks Biotherapeutics, Inc., situated in San Diego, California, specializes in pioneering new immunology-based treatments. The firm is actively involved in the discovery and progression of therapeutics aimed at combating autoimmune and inflammatory disorders, currently advancing programs like rosnilimab, ANB033, and ANB101 through their clinical stages.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
Insider Selling: First Tracks Biotherapeutics (NASDAQ:TRAX) Director Sells $1,758,286.70 in Stock
First Tracks Biotherapeutics (NASDAQ: TRAX - Get Free Report) Director J. Anthony Ware sold 39,265 shares of the firm's stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $44.
First Tracks Biotherapeutics Announces Participation in September Investor Conferences
SAN DIEGO, Aug. 26, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmun
First Tracks Biotherapeutics Analysts Increase Their Forecasts After Q2 Results
First Tracks Biotherapeutics Inc (NASDAQ:TRAX) reported a narrower loss for the second quarter on Wednesday.
First Tracks Biotherapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update
SAN DIEGO, Aug. 12, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmun
First Tracks Biotherapeutics (NASDAQ:TRAX) Receives Consensus Rating of “Moderate Buy” from Analysts
Shares of First Tracks Biotherapeutics (NASDAQ: TRAX - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the nine research firms that are covering the stock, Marketbeat.com reports. One